Figure 5
In vivo BLI of lux versus luc in additional models of S. aureus infection. (A,B) A mouse model of S. aureus skin infection was performed with inoculation of AH4826 (lux + luc) (1 × 108 CFU) i.d. into the back skin of mice (n = 10 mice/group). In vivo BLI imaging was performed ± administration of D-Luciferin (150 mg/kg s.c.) at 15–25 minutes prior to imaging the mice (n = 10/group). (A) Representative in vivo BLI. (B) In vivo BLI signals (photons/s) ± SEM. (C–E) A rabbit model of S. aureus orthopaedic implant associated infection (OIAI) was performed with inoculation of AH4826 (lux + luc) (1 × 104 CFU) into a femoral intramedullary canal prior to surgical placement of an orthopaedic-grade titanium locking peg (n = 6 rabbits/group) and in vivo BLI imaging was performed ± administration of D-Luciferin (150 mg/kg s.c.) at 15–25 minutes prior to imaging the rabbits. (C) Representative in vivo BLI. (D) In vivo BLI signals (photons/s) ± SEM. (E) Skin tissue from day 10 was homogenized and ex vivo CFU of AH4826 (lux + luc) was cultured on bacterial culture petri dishes overnight (n = 5 replicates) and BLI was performed for a 30 second acquisition time at 37 °C ± the addition of D-Luciferin (600 ng/200 µL PBS pipetted directly onto the surface of the plates) on an IVIS Lumina III (PerkinElmer) and representative BLI signals are provided with no filter (open) and with 520, 570, 620, 670 and 710 nm emission filters. *P < 0.05 between ± administration of D-Luciferin, as calculated by a 2-way ANOVA (B,D). n.s. = not significant.
